sevelamer
CLINICAL USE
Phosphate-binding agent
DOSE IN NORMAL RENAL FUNCTION
1–5 tablets (average: 3–5) 3 times a day with meals; adjust according to serum phosphate level
PHARMACOKINETICS
Molecular weight                           :Large %Protein binding                           :No data %Excreted unchanged in urine     : No data Volume of distribution (L/kg)       :No datahalf-life – normal/ESRD (hrs)      :No data DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function 10 to 20     : Dose as in normal renal function <10           : Dose as in normal renal function DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unlikely to be dialysed. Dose as in normal renal function HD                     :Unlikely to be dialysed. Dose as in normal renal functionHDF/high flux   :Unlikely to be dialysed. Dose as in normal renal functionCAV/VVHD      :Unlikely to be dialysed. Dose as in normal renal function IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsMycophenolate: may reduce mycophenolate levels ADMINISTRATION
Reconstition
– Route
Oral Rate of Administration
–Comments
– OTHER INFORMATION
Do not use if the patient has swallowing disorders or untreated or severe gastroparesisRenagel is not systemically absorbed One tablet = 800 mg of poly(allylamine hydrochloride) polymerCan be dispersed in 10 mL sodium bicarbonate 8.4% injection if patient is unable to take the tablets.
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home